Ribavirin News and Research

RSS

Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.

Scientists discover 70 existing drugs that block deadly hantavirus infections

Researchers screened over 5,000 compounds and successfully pinpointed 70 existing drugs, including unexpected beta-lactam antibiotics, that effectively suppress Puumala orthohantavirus infection in human cells. This milestone drug-repurposing study provides an immediate, fast-tracked pipeline for developing the first approved treatments against life-threatening hantavirus diseases.

28 Jun 2026

Nasal viruses may drive allergic rhinitis, and ribavirin shows early promise as a targeted spray treatment

Nasal commensal viruses may worsen allergic rhinitis by activating type I IFN-linked neutrophils and NET formation. Ribavirin reduced nasal viral abundance and improved symptoms in mice and in a small phase 2 trial.

28 Jun 2026

Colbopasvir plus sofosbuvir achieves high cure rates in chronic hepatitis C

In this real‑world multicenter study (Wenzhou, China), 113 chronic hepatitis C patients received colbopasvir (60 mg) + sofosbuvir (400 mg) daily for 12 weeks. Overall SVR12 was 99.1% (112/113). SVR12 was 100% for genotypes 3a, 3b, 6a, and compensated cirrhosis, 93.3% for genotype 1b, and 90% for HBV co‑infection.

14 May 2026

Hantavirus scare on cruise ship prompts WHO response

Hantavirus infections among cruise ship passengers have sparked a global health response, highlighting the need for effective outbreak management strategies.

7 May 2026

New approach identified for treating infections with Hepatitis E virus

Instead of directly attacking the virus, the compound acts on the host cell and prevents infection.

23 Apr 2026

Rat hepatitis E virus may be a hidden cause of hepatitis in humans

This Nature Communications review argues that rat hepatitis E virus is an emerging zoonotic cause of hepatitis that is likely underdiagnosed because current tests are limited and awareness remains low. It shows that ratHEV is widespread in urban rodent populations, can infect humans and some other animals, and may spread mainly through indirect environmental exposure rather than direct rodent contact.

12 Apr 2026

Coffee protects the liver by blocking inflammation and scarring, review finds

A new review in Biochemical Pharmacology synthesizes decades of research showing consistent links between regular coffee consumption and reduced risk of liver disease, including cirrhosis and liver cancer. Coffee’s bioactive compounds act on antioxidant, anti-inflammatory, antifibrotic, and metabolic pathways to slow liver damage progression.

21 Sep 2025

New guidelines improve care for respiratory infections in leukemia patients

People with leukemia have a weakened immune system due to the disease itself and treatment, which leads to an increased susceptibility to infections.

28 Aug 2025

Hepatitis E virus also attacks organs other than the liver, study finds

A research team from Bochum and Hannover shows that the hepatitis E virus also attacks organs other than the liver.

3 Jul 2025

Electroacupuncture may aid in personalized ribavirin dosing for long COVID

Various devices are used to study the unique electrical properties of acupuncture points (APs), with Voll's electropuncture diagnostics (EAV) occupying a prominent role.

21 Jan 2025

Review highlights the pathogenesis and clinical spectrum of Nipah virus infection

Nipah virus (NiV), a zoonotic paramyxovirus with significant human health implications, has garnered considerable attention due to its high fatality rates and potential for human-to-human transmission, posing a global public health threat.

15 Jan 2025

New insights into respiratory syncytial virus and prevention strategies

Respiratory syncytial virus (RSV) is a major cause of respiratory infections, particularly in infants, children under 5 years, and older adults. Its rapid spread makes RSV a serious public health concern. Currently, there are no effective medications for RSV, and current treatment focuses on providing supportive care and preventing its spread.

20 Dec 2024

Host RNA incorporation linked to chronic hepatitis E infection

If the virus incorporates host genetic segments into its genome, the infection may become chronic.

10 Jun 2024

Drug repurposing study finds lonafarnib effective against RSV

A study in Nature Communications identifies lonafarnib from the ReFRAME drug-repurposing library as a potent inhibitor of the RSV fusion protein, showing promise in reducing RSV infection in vitro and in vivo.

11 Feb 2024

Study provides valuable insights into the evolutionary dynamics of hepatitis E virus

A combination therapy with multiple drugs is more effective than just one active compound. To begin with, at least.

23 Jan 2024

RSV in seniors: Less common than COVID-19, but hits harder, CDC study reveals

In a recent CDC's MMWR study, researchers found that while respiratory syncytial virus (RSV) infections are less common than COVID-19 and influenza in Americans aged 60+ years, they result in much more severe clinical outcomes. This insight supports the CDC's recommendation for RSV vaccination in older adults, emphasizing its potential in preventing severe respiratory disease.

10 Oct 2023

The potential benefits of ribavirin and pleconaril treatment on type 1 diabetes

Researchers investigate whether ribavirin and pleconaril could stimulate endogenous insulin production among individuals with incident type 1 diabetes.

8 Oct 2023

Antiviral treatment emerges as a potential game-changer in curbing type 1 diabetes progression

New research from the University of Oslo reveals antiviral drugs could help preserve insulin production in children newly diagnosed with type 1 diabetes, potentially slowing down or even preventing the disease. The study, building on earlier findings linking enterovirus to type 1 diabetes, showed that antiviral treatment led to maintained insulin production, proposing a new therapeutic avenue to treat and mitigate the progression of type 1 diabetes.

3 Oct 2023